Recombinant Mouse VLDLR Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01217P-100UG

Mouse VLDLR on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Mouse VLDLR Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01217P-100UG
Collections: High-quality recombinant proteins, Other recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Mouse VLDLR Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gly28-Ser797. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | P98156 |
Target Symbol | VLDLR |
Synonyms | VLDL-R; VLDLR; RP11-320E16.1; CHRMQ1; FLJ35024; VLDLRCH |
Species | Mouse |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Gly28-Ser797 |
Mol. Weight | The protein has a predicted MW of 86.1 kDa. Due to glycosylation, the protein migrates to 110-130 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | The affinity constant of 0.28 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | VLDLR cerebellar hypoplasia (VLDLR-CH) is characterized by non-progressive congenital ataxia that is predominantly truncal and results in delayed ambulation, moderate-to-profound intellectual disability, dysarthria, strabismus, and seizures.VLDLR-CH is inherited in an autosomal recessive manner. Carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing are possible when the pathogenic variants in a family are known. |